Contents
Academy · Research Data, Analytics & AI · Researchers oppose COVID-19 genome data being open
Opposition to Fully Open COVID-19 Genome Data: Attribution and Contributor Incentives in Data-Sharing Policy
An open letter calling for fully open coronavirus genome data appeared, at face value, to advocate an uncontroversial public good. The researchers who objected advanced a specific, documented argument concerning who benefits from open access when attribution safeguards are removed.
During the COVID-19 pandemic, a documented public disagreement emerged among scientists over whether SARS-CoV-2 genome sequence data, held in platforms such as GISAID under terms requiring users to credit data-contributing laboratories, should instead be made fully openly accessible without those attribution requirements.
Learning objectives
- The substance of the disagreement, as reported.
- The specific concern researchers from lower-resourced settings raised about removing attribution requirements.
- The counter-argument made by proponents of fully open data.
- Reasons why this disagreement constitutes a genuine, documented policy debate rather than a simple open-versus-closed question.
Common misconceptions
- “Scientists universally support making all research data fully open with no conditions.” A documented 2021 disagreement, reported in Nature, showed researchers from lower-resourced settings specifically objecting to the removal of GISAID’s attribution requirements, out of concern that removal would allow better-resourced groups to publish analyses of their sequence data without appropriate credit or involvement.
- “Opposing unrestricted open data access means opposing data sharing altogether.” The researchers raising concerns were not opposed to sharing genome data (GISAID itself is a data-sharing platform) but specifically to the removal of the credit and involvement safeguards that the platform’s terms provided for the laboratories generating the sequences.
The substance of the disagreement
In 2021, approximately 800 researchers, predominantly from wealthier countries, signed an open letter calling for SARS-CoV-2 sequence data held on platforms such as GISAID to be made fully openly accessible, according to reporting in Nature. GISAID’s existing terms required anyone using deposited sequences to credit the contributing laboratories and, in practice, often to involve them in resulting analyses; the open letter’s signatories argued that removing this requirement would make genomic surveillance data more usable for pandemic response.
The attribution concern
Researchers objecting to the proposal, reported to include scientists from lower- and middle-income countries that had contributed substantial sequencing data, argued that removing the attribution and involvement requirement risked allowing better-resourced research groups to publish analyses built on their sequence data without appropriate credit, a concern distinct from opposition to data sharing itself. Glenda Gray, president of the South African Medical Research Council, was reported as warning that without these safeguards, researchers might revert to withholding data until after their own publication, which would slow rather than accelerate pandemic genomic surveillance.
The case for fully open access
Proponents of fully open access, including Rolf Apweiler, reported as co-director of the push for open data, argued that sequencing during a pandemic serves the public health response rather than individual researchers' career interests, and noted that lower- and middle-income countries' overall contribution to global sequence volume was comparatively small, which they argued limited how much the attribution concern should weigh against the practical benefits of fully open access. The dispute therefore turned on a genuine policy trade-off between maximising data usability and protecting the incentives and recognition of the researchers who generate the underlying data, rather than on a disagreement about the value of genomic surveillance itself.
Key points
Key points
The 2021 dispute over opening COVID-19 genome data was not a disagreement about whether to share sequence data, since platforms such as GISAID already did so, but a genuine policy trade-off between removing attribution and involvement safeguards to maximise usability and preserving those safeguards to protect the recognition and participation of the researchers, often in lower-resourced settings, who generate the sequences.
Practical application
Practical application
- The terms of a data-sharing dispute should be stated precisely. Discussion of a data-openness debate should specify which terms (attribution, embargo or involvement requirements) are contested, rather than framing the debate simply as open versus closed.
- Contributor incentives should be considered explicitly in the design of data-sharing policy. The design or evaluation of a data-sharing framework should consider how the removal of a specific safeguard affects the incentives of those generating the data, not only the convenience of those using it.
- Specific positions should be attributed accurately to their sources. Authors should report who raised a given concern and why, rather than characterising an entire research community as uniformly for or against open data.
Frequently asked questions
Reporting from this period describes the disagreement and the positions on each side; readers should check current GISAID policy directly for its present terms rather than assume a specific resolution.
No; the concern was specifically about removing attribution and involvement safeguards, not about whether genomic surveillance data should be shared at all.
GISAID was the specific platform at the centre of this reported 2021 dispute, though similar attribution-versus-openness trade-offs arise in other data-sharing contexts.
References
- Nature. Why some researchers oppose unrestricted sharing of coronavirus genome data. Nature News. 2021. read 10 October 2026. View on Nature
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). Opposition to Fully Open COVID-19 Genome Data: Attribution and Contributor Incentives in Data-Sharing Policy. Pubrica. https://pubrica.com/academy/concepts-definitions/researchers-oppose-covid-19-genome-data-being-open/
Pubrica Academy. “Opposition to Fully Open COVID-19 Genome Data: Attribution and Contributor Incentives in Data-Sharing Policy.” Pubrica, 10 Oct. 2026, pubrica.com/academy/concepts-definitions/researchers-oppose-covid-19-genome-data-being-open/.
Pubrica Academy (2026) Opposition to Fully Open COVID-19 Genome Data: Attribution and Contributor Incentives in Data-Sharing Policy. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/researchers-oppose-covid-19-genome-data-being-open/ (Accessed: 15 October 2026).
Pubrica Academy. “Opposition to Fully Open COVID-19 Genome Data: Attribution and Contributor Incentives in Data-Sharing Policy.” Pubrica. October 10, 2026. https://pubrica.com/academy/concepts-definitions/researchers-oppose-covid-19-genome-data-being-open/
Pubrica Academy, ‘Opposition to Fully Open COVID-19 Genome Data: Attribution and Contributor Incentives in Data-Sharing Policy’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/concepts-definitions/researchers-oppose-covid-19-genome-data-being-open/> accessed 15 October 2026.
Pubrica Academy. Opposition to Fully Open COVID-19 Genome Data: Attribution and Contributor Incentives in Data-Sharing Policy. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/researchers-oppose-covid-19-genome-data-being-open/
Pubrica Academy, “Opposition to Fully Open COVID-19 Genome Data: Attribution and Contributor Incentives in Data-Sharing Policy,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/researchers-oppose-covid-19-genome-data-being-open/
@misc{researchers_oppose_covid_genome_data_open_2026,
author = {{Pubrica Academy}},
title = {Opposition to Fully Open COVID-19 Genome Data: Attribution and Contributor Incentives in Data-Sharing Policy},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/researchers-oppose-covid-19-genome-data-being-open/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Data-sharing policy trade-off stub
This checklist applies to the design or evaluation of a data-sharing policy.
Data type and platform: ____ Current attribution/involvement terms: ____ Proposed change: ____ Benefit to data users of the proposed change: ____ Risk to data-generating contributors of the proposed change: ____ Stakeholders consulted: ____
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s research-policy team assists in weighing attribution, embargo and involvement terms when a data-sharing agreement is designed or negotiated, so that contributor incentives are considered alongside usability.